Business
Data at FNIH Biomarker Consortium Cancer Meeting
Data at FNIH Biomarker Consortium Cancer Meeting.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 4937W Oxford BioDynamics PLC 15 November 2017 \n\n \n \n15 November 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics presents latest immunotherapy data at the NIH Biomarker Consortium Cancer Steering Committee Annual Symposium, in Washington, DC\n \nEpiSwitchTM technology shows consistent profile of predictive biomarkers for response to immune checkpoint inhibitor therapy\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, presented its latest results at the annual meeting of the Foundation for National Institute for Health (FNIH) Biomarker Consortium Cancer Steering Committee, held in Washington, DC on 6-7 November 2017.\n \nIn the session dedicated to immune-oncology biomarkers, Dr A. Akoulitchev, Chief Scientific Officer of OBD, presented the results from three independent studies which showed a consistent profile of epigenetic markers for response to immune checkpoint inhibitor therapies, including anti-PD-L1 therapy Keytruda (Pembrolizumab) and several other anti-PD-L1 assets in two disease indications.\n \nBlind validation of an independent cohort of base line patients treated with an anti-PD-L1 therapeutic showed that OBD's EpiSwitch™ technology could predict response to treatment with a 83% positive predictive value (PPV). The biological relevance of identified epigenetic regulatory biomarkers for immunotherapy was strongly supported by their role in T-cell reinvigoration, survival, and proliferation to tumour burden.\n \nIt was also shown that a sub-group of the predictive EpiSwitch™ markers for response to treatment, identified and verified in over 57 patients, were associated to genes which are downstream of Interferon gamma stimulation. Another subgroup of biomarkers revealed high concordance with regulatory controls of MHC II receptors, known to play critical role in response to anti-PD-1 therapy. Full scope of the patient cohorts analysed by OBD will exceed 180 patients.\n \nFurther implications of EpiSwitchTM based approaches to patient stratifications were also discussed, ...